AstraZeneca and HUTCHMED Submit U.S. FDA Application for Orpathys-Tagrisso Lung Cancer Therapy

AstraZeneca and HUTCHMED have moved their MET-directed lung-cancer combination closer to the U.S. market after AstraZeneca submitted a New Drug Application to the Food and Drug Administration for Orpathys, also known as savolitinib, in combination with Tagrisso, or osimertinib. The filing seeks approval for patients with locally advanced or metastatic non-small cell lung cancer whose tumors show MET overexpression or amplification and whose disease progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

The submission matters because it targets a group of patients who can run out of options after developing resistance to EGFR-targeted therapy. HUTCHMED said the application is intended to support a biomarker-directed, all-oral treatment option for that setting. The companies are not saying the regimen is approved in the United States, only that the FDA filing has now been made and will need to go through the agency’s review process.

The application follows positive high-level results from the global SAFFRON Phase III trial that the companies disclosed in August. Those results gave the filing a defined clinical basis and also helped frame the commercial opportunity for AstraZeneca, which already markets Tagrisso and commercializes Orpathys under its collaboration with HUTCHMED.

SAFFRON results provide the basis for the FDA filing

According to AstraZeneca’s August announcement of the SAFFRON results, the combination of Tagrisso and Orpathys produced a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus platinum-based doublet chemotherapy in patients with EGFR-mutated non-small cell lung cancer who had developed MET-driven resistance after prior Tagrisso treatment. AstraZeneca said the safety profile was consistent with the known profiles of the two medicines and that no new safety findings emerged in the study.

That matters for the FDA filing because survival endpoints carry substantial weight in late-stage lung-cancer development. AstraZeneca described SAFFRON as the first global Phase III trial to show significant progression-free and overall survival benefits for this type of biomarker-selected population after progression on Tagrisso. The companies have also said the data will be presented in a Presidential Symposium at the European Society for Medical Oncology Congress 2026, which should give investors and clinicians a fuller view of the results beyond the topline statement released in August.

HUTCHMED had previously outlined the trial design in its SAFFRON enrollment update. The study randomized 338 patients, screened from more than 230 sites across 29 countries, and compared Orpathys 300 mg twice daily plus Tagrisso 80 mg once daily with platinum-based doublet chemotherapy. The primary endpoint was progression-free survival, while other endpoints included overall survival, objective response rate, duration of response, disease control rate, time to response and safety.

The breadth of the study matters because it gives the filing a global dataset rather than one limited to a single country or region. HUTCHMED had said when enrollment was completed in late 2025 that favorable results could support global regulatory filings. The companies are now acting on that plan in the United States.

The filing focuses on a common resistance pathway after EGFR therapy

The target population is narrower than the headline might suggest. This is not a broad filing for all patients with EGFR-mutated non-small cell lung cancer. Instead, it is aimed at patients whose tumors have MET overexpression or amplification, a resistance mechanism that can emerge after treatment with third-generation EGFR inhibitors. AstraZeneca has said one in three patients can develop high levels of MET overexpression or amplification after progression on a third-generation EGFR-TKI, leaving a significant need for more effective options once the original targeted approach stops working.

Tagrisso is already a core medicine in EGFR-mutated lung cancer, with approvals across multiple stages of disease, including first-line metastatic use. Orpathys is a selective MET tyrosine kinase inhibitor designed to block atypical activation of the MET pathway driven by gene amplification, protein overexpression and other alterations. Pairing the two drugs is intended to maintain EGFR suppression while also addressing the MET-driven escape pathway that can let the cancer resume growing.

That rationale helps explain why the companies have repeatedly described the combination as biomarker-directed and chemotherapy-free. For patients who meet the biomarker criteria, the companies are trying to position the regimen as an oral alternative to platinum-based chemotherapy rather than simply another empiric combination. Whether regulators ultimately agree will depend on the full data package, the magnitude of benefit, the safety profile and the practical reliability of the testing strategy used to identify eligible patients.

The biomarker point is also important for commercial expectations. Even if approved, the regimen would address a defined subgroup rather than the entire EGFR-mutated non-small cell lung-cancer market. That can still be commercially meaningful because Tagrisso already has a large installed base and MET-driven progression is a recognized resistance route, but the opportunity depends on testing uptake and physician willingness to treat the combination as a standard next step after resistance emerges.

Existing approvals and prior studies give the program context

The U.S. filing is not the first regulatory milestone for the combination. In June 2025, HUTCHMED announced China’s approval of Orpathys plus Tagrisso for patients with EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR-TKI therapy. That approval was based on the Phase III SACHI trial and triggered a milestone payment from AstraZeneca to HUTCHMED. The companies have also said the combination received a temporary authorization in Switzerland based on results from the global SAVANNAH Phase II trial.

Those earlier steps do not guarantee a U.S. approval, but they show the program is moving through a broader global regulatory strategy rather than beginning from scratch. They also reinforce the way the companies are building the franchise. Tagrisso remains the backbone product in EGFR-mutated lung cancer, while Orpathys is being layered in where MET biology becomes important in either resistance or earlier-line settings.

For HUTCHMED, the filing gives another example of how its pipeline can move from China-rooted development into international registration pathways through a larger commercial partner. For AstraZeneca, it adds another potential lifecycle expansion for Tagrisso and another chance to deepen its position in biomarker-led lung-cancer treatment. The next concrete milestone is likely to be FDA acceptance of the application for review, followed by the more detailed presentation of the SAFFRON results at ESMO.